David Charles Rees | |
---|---|
Born | 1958 (age 64–65) |
Alma mater | University of Southampton (BSc), University of Cambridge (PhD) |
Known for | Astex |
Awards | Royal Society of Chemistry, Malcolm Campbell Award 2007 [1] Royal Society of Chemistry BMCS Hall of Fame 2020 [2] ContentsRoyal Society of Chemistry BMCS Lectureship 2021/2022 [3] Fellowships Fellow of the Royal Society of Chemistry Fellow of the Academy of Medical Sciences (2020) |
Scientific career | |
Fields | Drug discovery, Medicinal chemistry, Organic chemistry |
Institutions | Astex, AstraZeneca, Organon |
Thesis | A new approach to the synthesis of aspidosperma alkaloids using tricarbonylcyclohexadienylium iron intermediates [4] |
Website | astx |
David Charles Rees (born 1958) CChem FRSC FMedSci is a chemist recognised internationally for his innovative use of chemistry in drug discovery. [5] He is Chief Scientific Officer of biotechnology company Astex Pharmaceuticals, which is located in Cambridge, UK.
Rees joined Astex in 2003 to lead its chemistry team. He became Chief Scientific Officer (CSO) in 2017. [6] In 2013, Astex was acquired for around USD $900 million [7] and now operates as a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd, headquartered in Tokyo, Japan.
Rees is associated with the discovery of three launched drugs: ribociclib (Astex-Novartis collaboration), [8] erdafitinib (Astex-Janssen collaboration) [9] as well as the anaesthetic reversal agent sugammadex (Organon, Merck), [10] which has been used in over 30 million patients in 60 countries and had global sales of US$1.2 billion in 2020. [11]
Rees has a BSc from the University of Southampton and PhD from the University of Cambridge.
Rees is a Fellow of the Royal Society of Chemistry (RSC). He is one of the few industrial scientists to have served as President of its Organic Division (2010-2013), and was later elected to the RSC Board of Trustees (2015-2019). [12]
Rees has held visiting professorships at three UK universities, and sits on several scientific advisory boards for not-for-profit organisations. In 2020 he was elected as a Fellow of the Academy of Medical Sciences and inducted into the RSC BMCS Hall of Fame. [13] He has over 140 publications and patents.
Rees is also a Director of Ashanti Development, a charity that promotes clean water and sanitation in Ghana.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
AstraZeneca plc is an Anglo-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.
The pharmaceutical industry is an industry in medicine that discovers, develops, produces, and markets pharmaceutical drugs for use as medications to be administered to patients, with the aim to cure and prevent diseases, or alleviate symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy using drug testing and marketing of drugs. The global pharmaceuticals market produced treatments worth $1,228.45 billion in 2020 and showed a compound annual growth rate (CAGR) of 1.8%.
Astex Pharmaceuticals ("Astex") is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
Pindaros Roy Vagelos is an American physician and business executive, who was president and chief executive officer (1985) and chairman (1986) of the American pharmaceutical company Merck & Co..
Bruce Eliot Maryanoff FRSC is an American medicinal and organic chemist.
Rubitecan is an oral topoisomerase inhibitor, developed by SuperGen.
Harren Jhoti is an Indian-born British structural biologist whose main interest has been rational drug design and discovery. He is president and chief executive officer (CEO) of biotechnology company Astex Pharmaceuticals ("Astex") which is located in Cambridge, United Kingdom.
Bayer AG is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The company is a component of the EURO STOXX 50 stock market index.
Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company, and a subsidiary of Otsuka Holdings, which focuses on developing cancer treatments. Taiho, headquartered in Tokyo, Japan, is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Dotmatics is an R&D scientific software company used by scientists in the R&D process that help them be more efficient in their efforts to innovate. Founded in 2005, the company's primary office is in Boston with 14 offices around the globe. In March 2021, Dotmatics joined forces with Insightful Science through a merger. In April 2022, the two companies consolidated under the Dotmatics brand. Dotmatics' software is used by 2 million scientists and researchers and 10,000 customers.
AMRI is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, AMRI operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. AMRI has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Co., Takeda, Genentech, Bristol-Myers Squibb Co. and GE.
Joshua S. Boger is an organic chemist and the founder of Vertex Pharmaceuticals Incorporated. He is considered a pioneer in the field of structure-based rational drug design. Drugs developed include amprenavir, an HIV protease inhibitor; telaprevir, a protease inhibitor for treatment of hepatitis C; and Kalydeco, for the treatment of cystic fibrosis. In 2003, Vertex was listed as one of forty worldwide Technology Pioneers by the World Economic Forum. As of 2012, Boger became executive chairman of Alkeus Pharmaceuticals.
Alessio Ciulli is an Italian British biochemist. Currently, he is the Professor of Chemical & Structural Biology at the School of Life Sciences, University of Dundee, where he founded and directs Dundee' new Centre for Targeted Protein Degradation (CeTPD). He is also the scientific co-founder and advisor of Amphista Therapeutics.
The Exploratory Science Center (ESC) is a pharmaceutical company based in Cambridge, MA. The disease agnostic research site was founded in 2016, and was led by Daria Hazuda until 2021. In late 2021 Juan Alvarez took on leadership as the interim head and Marc Levesque took on leadership in 2022. The Exploratory Science Center is a subsidiary of Merck & Co.
Fiona Hamilton Marshall is a British pharmacologist, founder and Senior Vice President of Discovery, Preclinical & Translational Medicine at Merck & Co. She will become the next president of the Novartis Institutes for BioMedical Research. She previously served as Chief Scientific Officer at Heptares Therapeutic, where she was Vice President of the Japanese biopharmaceutical company Sosei. She was elected Fellow of the Academy of Medical Sciences in 2016 and the Royal Society in 2021.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)